Jeffrey Westphal, 10% Owner at Vertex (NASDAQ:VERX), executed a substantial insider sell on November 14, according to an SEC filing. What Happened: Westphal's recent move involves selling ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

- First proteinuria data on povetacicept in primary membranous nephropathy shows mean UPCR reduction from baseline of 62% at 24 weeks – - Global Phase 3 RAINIER trial of povetacicept in IgA ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

But there was one company that kept at it. Fast-forward to today, and Vertex Pharmaceuticals is on the verge of gaining an FDA approval for suzetrigine (VX-548), a nonaddictive oral treatment that ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

Facial recognition technology is revolutionizing how consumers shop, travel and purchase. It is used to better secure airport, hospital, retail store and entertainment venue entry points.

If you’ve ever glanced in the mirror and noticed your face has ballooned in size, it can be a bit of a jump scare. After all, facial swelling isn’t as common as, say, a twitchy eyelid.

There's nothing quite like the way your skin looks after a professional facial — glowy, firmer, perfectly hydrated, your pores smaller and unclogged. And while facials are typically considered ...